Opthea Pty Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Stoneham MA United States (1983)

Organization Overview

First Clinical Trial
2012
NCT01514123
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Circadian Technologies | Circadian Technologies Ltd. | Opthea Limited

Active Ingredients

Drugs in Phase 3 Trials (3)

aflibercept (zaltrap) (2 trials)

opt-302 (5 trials)

ranibizumab (lucentis) (3 trials)

Drugs in Phase 1 Trials (2)

bevacizumab (avastin) (1 trial)

vgx-100 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 2)

Eye Diseases (Phase 1)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Neovascularization, Pathologic (Phase 1)

Retinal Degeneration (Phase 1)

Retinal Diseases (Phase 1)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5